Jefferies & Co Downgrades ResMed (RMD) to Hold
More News related to RMD
- Notable Analyst rating Changes for 02/05: RMD, WFR, ALKS, SFN, BEBE Upgraded; FWD, EGOV, LEAP, COH, CIEN Downgraded
- Morning Movers 2/5: ARG, KOOL, PWER, BEBE, END Higher; PFWD, EGOV, INPH, N, PTEC Lower
- Wells Fargo Upgrades ResMed (RMD) to Market Perform; Shares Fairly Valued
- After-Hours Movers 2/4: PWER, OPTR, PTIX, HA, TSYS Higher; PWAV, TTMI, MFLX, SNCR, BMI Lower
- ResMed (RMD) Tops Q2 EPS by 5c
More News related to Downgrades
- Wells Fargo Downgrades Parkway Properties (PKY) to Underperform
- Piper Jaffray Downgrades Telvent Git S.A. (TLVT) to Neutral; Recommend Sidelines on Potentially Weaker Spain Business
- S&P Lowers Pinnacle Entertainment (PNK) Outlook from Stable to Negative
- Mindspeed (MSPD) Moving Lower as Brigantine Downgrades to Hold
- Davenport Downgrades Electronic Arts (ERTS) to Sell; Lowers Q4, 2010-11 Estimates
Jefferies & Co downgrades ResMed (NYSE: RMD) from Buy to Hold. Price target increased from $50 to $53.
To see more analyst ratings on RMD Click Here.
ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders.
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
